Search research articles
Contact Us
Filters
Showing results (191-200 of 194) with videos related to
Page
of 20
Sort By:
You have reached the last page of results.
This site can display upto 194 results.
JCI Insight
|
January 17, 2020
miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2
Enrique Fuentes-Mattei, Recep Bayraktar, Taghi Manshouri, et al.
American Journal of Hematology
|
October 20, 2017
MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients
Adrian P Trifa, Claudia Bănescu, Anca S Bojan, et al.
Genome Research
|
March 24, 2018
Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA <i>CCAT2</i> induce myeloid malignancies via unique SNP-specific RNA mutations
Maitri Y Shah, Manuela Ferracin, Valentina Pileczki, et al.
Annals of Hematology
|
March 4, 2024
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
Jean-Jacques Kiladjian, Francisca Ferrer Marin, Haifa Kathrin Al-Ali, et al.
Page
of 20
Search research articles
Search
Showing results (191-200 of 194) with videos related to
Sort By:
Page
of 20
You have reached the last page of results.
This site can display upto 194 results.
JCI Insight
|
January 17, 2020
miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2
Enrique Fuentes-Mattei, Recep Bayraktar, Taghi Manshouri, et al.
American Journal of Hematology
|
October 20, 2017
MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients
Adrian P Trifa, Claudia Bănescu, Anca S Bojan, et al.
Genome Research
|
March 24, 2018
Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA <i>CCAT2</i> induce myeloid malignancies via unique SNP-specific RNA mutations
Maitri Y Shah, Manuela Ferracin, Valentina Pileczki, et al.
Annals of Hematology
|
March 4, 2024
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
Jean-Jacques Kiladjian, Francisca Ferrer Marin, Haifa Kathrin Al-Ali, et al.
Page
of 20